Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tripegfilgrastim PK/PD in Pediatric Solid Tumor/Lymphoma
NCT02963389Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Oct 2016
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegteograstim in neutropenia (4 arms), sponsored by Dong-A ST. Primary endpoint: Pharmacokinetic parameters. Started Oct 2016; status: completed.
02
Drugs
pegteograstim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02963389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963389.